Biota targets the sniffles
Monday, 11 August, 2008
Melbourne's Biota Holdings (ASX: BTA) has commenced dosing in an early stage trial of BTA798, an orally delivered inhibitor of human rhinovirus (HRV), a major cause of the common cold.
The UK based trial is aimed at evaluating BTA798 as a prophylactic against HRV infection in 200 health volunteers, who will receive a placebo or one of three dose levels before exposure to an experimental rhinovirus infection.
The drug candidate is designed to bind to clefts on the surface of the virus's capsid shell and interfere with attachment to receptors.
Results are expected in April next year.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
